Atherosclerosis Protocol

CardiovascularModerate Evidence

supplements

Primary

Supporting

Grade A

108

Studies

Primary Stack

Core supplements with strongest evidence

BerberineA

500mg three times daily

Activates AMPK to reduce LDL cholesterol, inhibits PCSK9, and reduces arterial inflammation

↓C-Reactive Protein (CRP)↓Total cholesterol↓Triglycerides↑High-density lipoprotein (HDL)↓Interleukin 6

27 studies2,569 participants

Supporting Studies (2)

PMID: 26488351 - Efficacy of berberine in dyslipidemia (2015)PMID: 22072781 - Berberine and cardiovascular disease (2011)

Omega-3 Fatty Acids (EPA/DHA)A

2-4g EPA/DHA daily

Reduces triglycerides, stabilizes plaque, and decreases vascular inflammation

45 studies75,000 participants

Supporting Studies (2)

PMID: 30415628 - REDUCE-IT trial: EPA cardiovascular outcomes (2019)PMID: 29773200 - Omega-3 fatty acids and cardiovascular disease (2018)

Supporting Stack

Additional supplements for enhanced results

Aged Garlic ExtractB

1200-2400mg daily

Reduces arterial plaque progression and improves endothelial function via H2S signaling

8 studies450 participants

Supporting Studies (1)

PMID: 26764327 - Aged garlic extract reduces coronary plaque (2016)

Vitamin K2 (MK-7)B

180-200mcg daily

Activates matrix Gla protein (MGP) to prevent arterial calcification

↑Apolipoprotein AAdiponectin↓Blood glucose↓C-Reactive Protein (CRP)↑High-density lipoprotein (HDL)

6 studies890 participants

Supporting Studies (1)

PMID: 25694037 - Vitamin K2 and vascular calcification (2015)

Niacin (Vitamin B3)B

1000-2000mg daily (extended-release)

Raises HDL cholesterol, lowers LDL and Lp(a), and has anti-inflammatory effects

↑Apolipoprotein A↓Apolipoprotein B↑Heart Attack Risk↑High-density lipoprotein (HDL)↓Low-density lipoprotein (LDL)

12 studies3,200 participants

Supporting Studies (1)

PMID: 20008623 - Niacin and cardiovascular outcomes (2010)

Coenzyme Q10B

200-300mg daily

Protects LDL from oxidation and supports endothelial function

10 studies650 participants

How This Protocol Works

Simple Explanation

Atherosclerosis is the buildup of cholesterol-rich plaques in arteries, driven by inflammation, oxidized LDL, and arterial calcification. This protocol targets all three mechanisms.

•Berberine is as effective as statins for lowering LDL cholesterol (15-20% reduction) but works through different mechanisms—it activates AMPK and increases LDL receptor expression. It also reduces arterial inflammation.

•Omega-3s (EPA/DHA) reduce triglycerides by 25-30%, stabilize existing plaques (making them less likely to rupture), and reduce the inflammation that drives plaque formation. The REDUCE-IT trial showed high-dose EPA reduced cardiovascular events by 25%.

•Aged garlic extract has been shown in CT imaging studies to slow plaque progression by 80% compared to placebo over 12 months.

•Vitamin K2 directs calcium away from arteries and into bones. Low K2 status is associated with arterial calcification.

•Niacin raises HDL ("good" cholesterol) and is the only agent that significantly lowers Lp(a), an independent risk factor.

•CoQ10 protects LDL particles from oxidation—it's oxidized LDL that gets deposited in artery walls.

Expected timeline: Lipid improvements in 4-8 weeks. Plaque stabilization/regression requires 12+ months of consistent use.

Clinical Perspective

Atherosclerosis pathogenesis involves endothelial dysfunction, LDL oxidation and subendothelial deposition, macrophage foam cell formation, and eventual plaque calcification. This protocol addresses multiple stages.

•Berberine (A-grade): Activates AMPK, upregulating LDLR expression and reducing PCSK9 (increasing LDL clearance). Also inhibits NF-κB, reducing vascular inflammation. Meta-analysis: LDL reduction 20-25mg/dL, TG reduction 40-50mg/dL (PMID: 26488351). Dose: 500mg TID with meals.

•Omega-3 EPA/DHA (A-grade): Incorporate into cell membranes, reducing arachidonic acid-derived inflammatory eicosanoids. High-dose EPA (4g/day icosapent ethyl) reduced MACE by 25% in REDUCE-IT (PMID: 30415628). Also reduces TG via decreased hepatic VLDL secretion.

•Aged Garlic Extract (B-grade): Provides S-allyl cysteine, which enhances H2S production, improving endothelial function. CT angiography studies show 80% reduction in plaque progression rate (PMID: 26764327).

•Vitamin K2 MK-7 (B-grade): Carboxylates matrix Gla protein (MGP), a potent inhibitor of vascular calcification. Rotterdam Study showed inverse correlation between K2 intake and coronary calcification.

•Niacin (B-grade): Inhibits diacylglycerol acyltransferase 2 (DGAT2), reducing hepatic TG synthesis. Uniquely raises HDL and lowers Lp(a) by 20-30%.

•CoQ10 (B-grade): Lipid-soluble antioxidant that prevents LDL oxidation in the vessel wall. Also improves endothelial function via enhanced NO bioavailability.

Biomarker targets: LDL-C <100 mg/dL, TG <150 mg/dL, HDL >40 mg/dL, hs-CRP <2 mg/L, Lp(a) reduction.

Monitoring: Lipid panel every 8-12 weeks initially. Consider coronary calcium score (CAC) for baseline.

View All Protocols